Hypercalcemia due to vitamin D toxicity

Vitamin D

Volumn , Issue , 2011, Pages 1381-1402

  Cusano, Natalie E ^a   Thys Jacobs, Susan ^a   Bilezikian, John P ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872586729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10072-1     Document Type: Chapter

References (239)

1. Barger-Lux M.J., Heaney R.P., Dowell S., Chen T.C., Holick M.F. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos. Int. 1998, 8(3):222-230.
2. Vieth R. The mechanisms of vitamin D toxicity. Bone Miner. 1990, 11(3):267-272.
3. Jacobus C.H., Holick M.F., Shao Q., Chen T.C., Holm I.A., Kolodny J.M., et al. Hypervitaminosis D associated with drinking milk. N. Engl. J. Med. 1992, 326(18):1173-1177.
4. 3 and its analogs in the treatment of psoriasis. Retinoids 1998, 14:12-17.
5. Koutkia P., Chen T.C., Holick M.F. Vitamin D intoxication associated with an over-the-counter supplement. N. Engl. J. Med. 2001, 345(1):66-67.
6. Lagman R., Walsh D. Dangerous nutrition? Calcium, vitamin D, shark cartilage nutritional supplements and cancer-related hypercalcemia. Support Care Cancer 2003, 11(4):232-235.
7. Drinka P.J., Moore J., Boushon M.C. Severe hypercalcemia after transition from calcium carbonate to calcium citrate in an elderly woman treated with ergocalciferol 50,000 IU per day. Am. J. Geriatr. Pharmacother. 2006, 4(1):70-74.
8. Carlton S., Clopton D., Cappuzzo K.A. Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity. Consult. Pharm. 2010, 25(3):171-177.
9. Leu J.P., Weiner A., Barzel U. Vitamin D toxicity: caveat emptor. Endocr. Pract. 2008, 14(9):1188-1190.
10. Lowe H., Cusano N.E., Binkley N., Blaner W.S., Bilezikian J.P. Vitamin D toxicity due to a commonly available "over the counter" remedy from the Dominican Republic. J. Clin. Endocrinol. Metab. 2011, 96(2):291-295.
11. Haddad J.G., Chyu K.J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 1971, 33(6):992-995.
12. Binkley N., Novotny R., Krueger D., Kawahara T., Daida Y.G., Lensmeyer G., et al. Low vitamin D status despite abundant sun exposure. J. Clin. Endocrinol. Metab. 2007, 92(6):2130-2135.
13. Tangpricha V., Koutkia P., Rieke S.M., Chen T.C., Perez A.A., Holick M.F. Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. Am. J. Clin. Nutr. 2003, 77(6):1478-1483.
14. Vieth R., Pinto T.R., Reen B.S., Wong M.M. Vitamin D poisoning by table sugar. Lancet 2002, 359(9307):672.
15. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab. 2004, 89(11):5387-5391.
16. Holick M.F., Biancuzzo R.M., Chen T.C., Klein E.K., Young A., Bibuld D., et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrinol. 2008, 93(3):677-681.
17. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357(3):266-281.
18. American Medical Women's Association Expert panel. An In-Depth Discussion of Vitamin D for Men & Women over 50 June 9, 2005.
19. Dawson-Hughes B., Mithal A., Bonjour J.P., Boonen S., Burckhardt P., Fuleihan G.E., et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010, 21(7):1151-1154.
20. Heaney R.P., Holick M.F. Why the IOM recommendations for vitamin D are deficient. J. Bone Miner. Res. 2011, 26(3):455-457.
21. Khosla S. What do we tell our patients about calcium and vitamin D supplementation. J. Clin. Endocrinol. Metab. 2011, 69(1):69-71.
22. Reid I.R., Avenell A. Evidence-based policy on dietary calcium and vitamin D. J. Bone Miner. Res. 2011, 26(3):452-454.
23. Heaney R.P. Vitamin D, nutritional deficiency, and the medical paradigm. J. Clin. Endocrinol. Metab. 2003, 88(11):5107-5108.
24. Hagenau T., Vest R., Gissel T.N., Poulsen C.S., Erlandsen M., Mosekilde L., et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos. Int. 2009, 20(1):133-140.
25. Silverberg S.J., Lewiecki E.M., Mosekilde L., Peacock M., Rubin M.R. Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J. Clin. Endocrinol. Metab. 2009, 94(2):351-365.
26. Rao D.S., Honasoge M., Divine G.W., Phillips E.R., Lee M.W., Ansari M.R., et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J. Clin. Endocrinol. Metab. 2000, 85(3):1054-1058.
27. Moosgaard B., Christensen S.E., Vestergaard P., Heickendorff L., Christiansen P., Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 2008, 68(5):707-715.
28. Inoue Y., Kaji H., Hisa I., Tobimatsu T., Naito J., Iu M.F., et al. Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr. J. 2008, 55(1):57-65.
29. Nordenström E., Westerdahl J., Lindergård B., Lindblom P., Bergenfelz A. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J. Surg. 2002, 26(12):1463-1467.
30. Rao D.S., Agarwal G., Talpos G.B., Phillips E.R., Bandeira F., Mishra S.K., et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J. Bone Miner. Res. 2002, 17(Suppl 2):N75-N80.
31. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin Endocrinol. Metab. 2005, 90(4):2122-2126.
32. Tucci J.R. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur. J. Endocrinol. 2009, 161(1):189-193.
33. Grubbs E.G., Rafeeq S., Jimenez C., Feng L., Lee J.E., Evans D.B., et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?. Surgery 2008, 144(6):852-858.
34. Isidro M.L., Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009, 36(2):305-310.
35. Administration F.a.D, Over the Counter Report Federal Register 1979, 16164-16169.
36. Barger-Lux M.J., Heaney R.P., Dowell S., Chen T.C., Holick M.F. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos. Int. 1998, 8(3):222-230.
37. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 2003, 77(1):204-210.
38. Hathcock J.N., Shao A., Vieth R., Heaney R. Risk assessment for vitamin D. Am. J. Clin. Nutr. 2007, 85(1):6-18.
39. Parfitt A.M., Gallagher J.C., Heaney R.P., Johnston C.C., Neer R., Whedon G.D. Vitamin D and bone health in the elderly. Am. J. Clin. Nutr. 1982, 36(Suppl. 5):1014-1031.
40. National Kidney Foundation K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003, 42(4 Suppl. 3):S1-201.
41. Kriebitzsch C., Verlinden L., Eelen G., Tan B.K., Van Camp M., Bouillon R., et al. The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells - a microarray approach. Anticancer Res. 2009, 29(9):3471-3483.
42. Chung M., Balk E.M., Brendel M., Ip S., Lau J., Lee J., et al. Vitamin D and Calcium: Systematic Review of Health Outcomes. Evidence Report/Technology Assessment No. 183. AHRQ Publication No. 09-E015 2009, Agency for Healthcare Research and Quality, Rockville, MD.
43. Aloia J.F., Vaswani A., Yeh J.K., Ellis K., Yasumura S., Cohn S.H. Calcitriol in the treatment of postmenopausal osteoporosis. Am. J. Med. 1988, 84(3 Pt 1):401-408.
44. Christiansen C., Rodbro P., Christensen M.S., Hartnack B., Transbol I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 1978, 2(8092 Pt 1):700-703.
45. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J. Clin. Invest. 1984, 74(6):2136-2143.
46. Caravaca F., Cubero J.J., Jimenez F., Lopez J.M., Aparicio A., Cid M.C., et al. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uremic patients with secondary hyperparathyroidism. Nephrol. Dial Transplant. 1995, 10(5):665-670.
47. Monier Faugere M.C., Malluche H.H. Calcitriol pulse therapy in patients with end-stage renal failure. Curr. Opin. Nephrol. Hypertens. 1994, 3(6):615-619.
48. Juergensen P., Santacroce S., Mooraki A., Cooper K., Finkelstein F.O., Kliger A.S. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients. Adv. Perit. Dial 1994, 10:259-260.
49. 3 for control of secondary hyperparathyroidism. Pediatr. Nephrol. 1994, 8(6):724-726.
50. Crocker J.F., Muhtadie S.F., Hamilton D.C., Cole D.E. The comparative toxicity of vitamin D metabolites in the weanling mouse. Toxicol. Appl. Pharmacol. 1985, 80(1):119-126.
51. 3 in man. J. Clin. Invest. 1976, 57(6):1540-1547.
52. Kanis J.A., Russell R.G., Smith R. Physiological and therapeutic differences between vitamin D, its metabolites, and analogs. Clin. Endocrinol. (Oxf.) 1977, 7(Suppl):191s-201s.
53. Mortensen J.T., Brinck P., Binderup L. Toxicity of vitamin D analogs in rats fed diets with standard or low calcium contents. Pharmacol. Toxicol. 1993, 72(2):124-127.
54. 2 on calcium homeostasis in postmenopausal osteopenic women. J. Bone Miner. Res. 1994, 9(5):607-614.
55. 3 in the rat. Proc. Soc. Exp. Biol. Med. 1985, 178(3):432-436.
56. Pols H.A., Birkenhager J.C., van Leeuwen J.P. Vitamin D analogs: from molecule to clinical application. Clin. Endocrinol. (Oxf.) 1994, 40(3):285-292.
57. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 1995, 16(2):200-257.
58. Wu-Wong J.R., Nakane M., Gagne G.D., Brooks K.A., Noonan W.T. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int. J. Endocrinol. Epub. Mar. 2010, 2.
59. Salusky I.B., Goodman W.G. Cardiovascular calcification in end-stage renal disease. Nephrol. Dial Transplant. 2002, 17(2):336-339.
60. Mathew S., Lund R.J., Chaudhary L.R., Geurs T., Hruska K.A. Vitamin D receptor activators can protect against vascular calcification. J. Am. Soc. Nephrol. 2009, 19(8):1509-1519.
61. Palmer S.C., McGregor D.O., Craig J.C., Elder G., Macaskill P., Strippoli G.F. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst. Rev. 2009, 7(4). CD005633.
62. Malluche H.H., Monier Faugere M.C., Koszewski N.J. Use and indication of vitamin D and vitamin D analogs in patients with renal bone disease. Nephrol. Dial Transplant. 2002, 17(Suppl. 10):6-9.
63. Andress D.L. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008, 73(12):1345-1354.
64. Nakane M., Fey T.A., Dixon D.B., Ma J., Brune M.E., Li Y.C., et al. Differential effects of vitamin D analogs on bone formation and resorption. J. Steroid Biochem. Mol. Biol. 2006, 98(1):72-77.
65. Brown A.J., Finch J., Grieff M., Ritter C., Kubodera N., Nishii Y., et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993, 133(3):1158-1164.
66. Braun G.S., Witt M., Mayer V., Schmid H. Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment. Int. J. Dermatol. 2007, 46(12):1315-1317.
67. Kawahara C., Okada Y., Tanikawa T., Fukusima A., Misawa H., Tanaka Y. Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis. J. Bone Miner. Metab. 2004, 22(2):159-162.
68. Bourke J.F., Berth-Jones J., Mumford R., Iqbal S.J., Hutchinson P.E. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels. Clin. Endocrinol. (Oxf.) 1994, 41(3):295-297.
69. Dwyer C., Chapman R.S. Calcipotriol and hypercalcemia. Lancet 1991, 338(8769):764-765.
70. Online Mendelian Inheritance in Man MIM no. 194050 2003, Johns Hopkins University, Baltimore, MD, Available at: www.ncbi.nlm.nih.gov/omim. (Accessed July 19, 2010).
71. Taylor A.B., Stern P.H., Bell N.H. Abnormal regulation of circulating 25-hydroxyvitamin D in the Williams syndrome. N. Engl. J. Med. 1982, 306(16):972-975.
72. Cagle A.P., Waguespack S.G., Buckingham B.A., Shankar R.R., Dimeglio L.A. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate. Pediatrics 2004, 114(4):1091-1095.
73. Omdahl J., Holick M., Suda T., Tanaka Y., DeLuca H.F. Biological activity of 1,25-dihydroxycholecalciferol. Biochemistry 1971, 10(15):2935-2940.
74. Papapoulos S.E., Clemens T.L., Fraher L.J., Lewin I.G., Sandler L.M., O'Riordan J.L. 1,25-dihydroxycholecalciferol in the patho-genesis of the hypercalcemia of sarcoidosis. Lancet 1979, 1(8117):627-630.
75. Harrel G., Fisher S. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium, and phosphate values. J. Clin. Invest. 1939, 18:687-693.
76. Studdy P.R., Bird R., Neville E., James D.G. Biochemical findings in sarcoidosis. J. Clin. Pathol. 1980, 33(6):528-533.
77. Rizzato G. Clinical impact of bone and calcium changes in sarcoidosis. Thorax. 1998, 53(5):139-142.
78. Anderson J., Harper C., Dent C.E., Philpot G.R. Effect of cortisone on calcium metabolism in sarcoidosis with hypercalcemia; possibly antagonistic actions of cortisone and vitamin D. Lancet 1954, 267(6841):720-724.
79. Albright F., Carroll E.L., Dempsey E.F., Henneman P.H. The cause of hypercalcuria in sarcoid and its treatment with cortisone and sodium phytate. J. Clin. Invest. 1956, 35(11):1229-1242.
80. Taylor R.L., Lynch H.J., Wysor W.G. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. Am. J. Med. 1963, 34(2):221-227.
81. Bell N.H., Stern P.H., Pantzer E., Sinha T.K., DeLuca H.F. Evidence that increased circulating 1α,25-dihydroxy-vitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J. Clin. Invest. 1979, 64(1):218-225.
82. Barbour G.L., Coburn J.W., Slatopolsky E., Norman A.W., Horst R.L. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 1981, 305(8):440-443.
83. Maesaka J.K., Batuman V., Pablo N.C., Shakamuri S. Elevated 1,25-dihydroxyvitamin D levels: occurrence with sarcoidosis with end-stage renal disease. Arch. Intern. Med. 1982, 142(6):1206-1207.
84. Adams J.S., Gacad M.A., Anders A., Endres D.B., Sharma O.P. Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis. Sarcoidosis 1986, 3(1):1-6.
85. Adams J.S. Vitamin D metabolite-mediated hypercalcemia. Endocrinol. Metab. Clin. North Am. 1989, 18(3):765-778.
86. 3 and parameters of disease activity. Q. J. Med. 1985, 54(215):269-281.
87. Mason R.S., Frankel T., Chan Y.L., Lissner D., Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann. Intern. Med. 1984, 100(1):59-61.
88. 3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 1983, 72(5):1856-1860.
89. 3 produced by cultured alveolar macrophages in sarcoidosis. J. Clin. Endocrinol. Metab. 1985, 60(5):960-966.
90. 3 1α-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am. J. Med. 2001, 110(9):687-693.
91. 3-1α-hydroxylase gene. Proc. Natl. Acad. Sci. USA 1999, 96(12):6988-6993.
92. Dusso A.S., Kamimura S., Gallieni M., Zhong M., Negrea L., Shapiro S., et al. Gamma-interferon-induced resistance to 1,25-(OH)2D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J. Clin. Endocrinol. Metab. 1997, 82(7):2222-2232.
93. 3 1α-hydroxylase gene expression in macrophages. Kidney Int. 2000, 58(2):559-568.
94. Vidal M., Ramana C.V., Dusso A.S. Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol. Cell Biol. 2002, 22(8):2777-2787.
95. Bell N.H., Gill J.R., Bartter F.C. On the abnormal calcium absorption in sarcoidosis: evidence for increased sensitivity to vitamin D. Am. J. Med. 1964, 36(4):500-513.
96. Basile J.N., Liel Y., Shary J., Bell N.H. Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis. J. Clin. Invest. 1993, 91(4):1396-1398.
97. 3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J. Clin. Endocrinol. Metab. 1987, 65(6):1201-1209.
98. Fuss M., Pepersack T., Gillet C., Karmali R., Corvilain J. Calcium and vitamin D metabolism in granulomatous diseases. Clin. Rheumatol. 1992, 11(1):28-36.
99. Jackson W.P., Dancaster C. A consideration of the hypercalciuria in sarcoidosis, idiopathic hypercalciuria, and that produced by vitamin D; a new suggestion regarding calcium metabolism. J. Clin. Endocrinol. Metab. 1959, 19(6):658-680.
100. Bell N.H., Bartter F.C. Studies of 47-Ca metabolism in sarcoidosis: evidence for increased sensitivity of bone to vitamin D. Acta. Endocrinol. (Copenh.) 1967, 54(1):173-180.
101. Dwarakanathan A., Ryan W.G. Hypercalcemia of sarcoidosis treated with cellulose sodium phosphate. Bone Miner. 1987, 2(4):333-336.
102. Insogna K.L., Dreyer B.E., Mitnick M., Ellison A.F., Broadus A.E. Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis. J. Clin. Endocrinol. Metab. 1988, 66(1):72-75.
103. Fallon M.D., Perry H.M., Teitelbaum S.L. Skeletal sar-coidosis with osteopenia. Metab. Bone Dis. Relat. Res. 1981, 3(3):171-174.
104. Alexandre C., Chappard D., Vergnon J.M., Emonot A., Riffat G. The bone in noncorticoid-treated sarcoidosis. A histomorphometric study. Rev. Rhum. Mal. Osteoartic. 1987, 54(2):159-162.
105. Scholz D.A., Keating F.R. Renal insufficiency, renal calculi, and nephrocalcinosis in sarcoidosis; report of eight cases. Am. J. Med. 1956, 21(1):75-84.
106. 3. Q. J. Med. 1984, 53(210):165-180.
107. Zeimer H.J., Greenaway T.M., Slavin J., Hards D.K., Zhou H., Doery J.C., et al. Parathyroid-hormone-related protein in sarcoidosis. Am. J. Pathol. 1998, 152(1):17-21.
108. Abbasi A.A., Chemplavil J.K., Farah S., Muller B.F., Arnstein A.R. Hypercalcemia in active pulmonary tuberculosis. Ann. Intern. Med. 1979, 90(3):324-328.
109. Sharma S.C. Serum calcium in pulmonary tuberculosis. Postgrad. Med. J. 1981, 57(673):694-696.
110. Kitrou M.P., Phytou Pallikari A., Tzannes S.E., Virvidakis K., Mountokalakis T.D. Hypercalcemia in active pulmonary tuberculosis. Ann. Intern. Med. 1982, 96(2):255.
111. Davies P.D., Brown R.C., Woodhead J.S. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax. 1985, 40(3):187-190.
112. Fuss M., Karmali R., Pepersack T., Bergans A., Dierckx P., Prigogine T., et al. Are tuberculous patients at a great risk from hypercalcemia?. Q. J. Med. 1988, 69(259):869-878.
113. Chan T.Y., Chan C.H., Shek C.C., Davies P.D. Hypercalcemia in active pulmonary tuberculosis and its occurrence in relation to the radiographic extent of disease. Southeast Asian J. Trop. Med. Public Health 1992, 23(4):702-704.
114. Tan T.T., Lee B.C., Khalid B.A. Low incidence of hypercalcaemia in tuberculosis in Malaysia. J. Trop. Med. Hyg. 1993, 96(6):349-351.
115. Kelestimur F., Guven M., Ozesmi M., Pasaoglu H. Does tuberculosis really cause hypercalcemia?. J. Endocrinol. Invest. 1996, 19(10):678-681.
116. Chan T.Y. Differences in vitamin D status and calcium intake: possible explanations for the regional variations in the prevalence of hypercalcemia in tuberculosis. Calcif. Tissue Int. 1997, 60(1):91-93.
117. Felsenfeld A.J., Drezner M.K., Llach F. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch. Intern. Med. 1986, 146(10):1941-1945.
118. 3 levels in a dialysis patient with disseminated tuberculosis. Nephron 1987, 46(4):377-379.
119. Shai F., Baker R.K., Addrizzo J.R., Wallach S. Hypercalcemia in mycobacterial infection. J. Clin. Endocrinol. Metab. 1972, 34(2):251-256.
120. Barnes P.F., Modlin R.L., Bikle D.D., Adams J.S. Transpleural gradient of 1,25-dihydroxyvitamin D in tuberculous pleuritis. J. Clin. Invest. 1989, 83(5):1527-1532.
121. Adams J.S., Modlin R.L., Diz M.M., Barnes P.F. Potentiation of the macrophage 25-hydroxyvitamin D-1-hydroxylation reaction by human tuberculous pleural effusion fluid. J. Clin. Endocrinol. Metab. 1989, 69(2):457-460.
122. Cadranel J., Garabedian M., Milleron B., Guillozo H., Akoun G., Hance A.J. 1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J. Clin. Invest. 1990, 85(5):1588-1593.
123. Liu P.T., Stenger S., Huiying L., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311(5768):1770-1773.
124. Saggese G., Bertelloni S., Baroncelli G.I., Di Nero G. Ketoconazole decreases the serum ionized calcium and 1,25-dihydroxyvitamin D levels in tuberculosis-associated hypercalcemia. Am. J. Dis. Child. 1993, 147(3):270-273.
125. Couri C.E., Foss N.T., Dos Santos C.S., de Paula F.J. Hypercalcemia secondary to leprosy. Am. J. Med. Sci. 2004, 328(6):357-359.
126. Magill S.B., Schmahl T.M., Sommer J., Doos W.G., Pellegrini J.G., Shaker J.L. Coccidioidomycosis-induced thyroiditis and calcitriol-mediated hypercalcemia in a heart transplantation patient. Endocrinologist 1998, 8(4):299-302.
127. Liang K.V., Ryu J.H., Matteson E.L. Histoplasmosis with tenosynovitis of the hand and hypercalcemia mimicking sarcoidosis. J. Clin. Rheumatol. 2004, 10(3):138-142.
128. Kantarjian H.M., Saad M.F., Estey E.H., Sellin R.V., Samaan N.A. Hypercalcemia in disseminated candidiasis. Am. J. Med. 1983, 74(4):721-724.
129. Bosch X. Hypercalcemia due to endogenous overproduction of active vitamin D in identical twins with cat-scratch disease. JAMA 1998, 279(7):532-534.
130. Ahmed B., Jaspan J.B. Case report: hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am. J. Med. Sci. 1993, 306(5):313-316.
131. 3 levels associated with disseminated Mycobacterium avium infection in AIDS. J. Infect. 2001, 42(2):157-158.
132. Almeida R.M., Cezana L., Tsukumo D.M., de Carvalho-Filho M.A., Saad M.J. Hypercalcemia in a patient with disseminated paracoccidioidomycosis: a case report. J. Med. Case Reports 2008, 2:262-263.
133. Schattner A., Gilad A., Cohen J. Systemic granulomatosis and hypercalcemia following intravesical bacillus Calmette-Guerin immunotherapy. J. Intern. Med. 2002, 251(3):272-277.
134. Bosch X., López-Soto A., Morelló A., Olmo A., Urbano-Márquez A. Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Mayo. Clin. Proc. 1997, 72(5):440-444.
135. Al-Ali H., Yabis A.A., Issa E., Salem Z., Tawil A., Khoury N. Hypercalcemia in Langerhans' cell granulomatosis with elevated 1,25 dihydroxyvitamin D (calcitriol) level. Bone 2002, 30(1):331-334.
136. Tuohy K.A., Steinman T.I. Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease. Am. J. Kidney Dis. 2005, 45(1):e3-e6.
137. Finne P.H., Sanderud J., Aksnes L., Bratlid D., Aarskog D. Hypercalcemia with increased and unregulated 1,25-dihydroxyvitamin D production in a neonate with subcutaneous fat necrosis. J. Pediatr. 1988, 112(5):792-794.
138. Kallas M., Green F., Hewison M., White C., Kline G. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J. Clin. Endocrinol. Metab. 2010, 95(7):3111-3117.
139. Stoeckle J.D., Hardy H.L., Weber A.L. Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am. J. Med. 1969, 46(4):545-561.
140. Kozeny G.A., Barbato A.L., Bansal V.K., Vertuno L.L., Hano J.E. Hypercalcemia associated with silicone-induced granulomas. N. Engl. J. Med. 1984, 311(17):1103-1105.
141. Albitar S., Genin R., Fen-Chong M., Schohn D., Riviere J.P., Serveaux M.O., et al. Multisystem granulomatous injuries 28 years after paraffin injections. Nephrol. Dial Transplant. 1997, 12(9):1974-1976.
142. Woywodt A., Schneider W., Goebel U., Luft F.C. Hypercalcemia due to talc granulomatosis. Chest 2000, 117(4):1195-1196.
143. Evron E., Goland S., von der Walde J., Schattner A., Sthoeger Z.M. Idiopathic calcitriol-induced hypercalcemia. A new disease entity?. Arch. Intern. Med. 1997, 157(18):2142-2145.
144. Saunders M.P., Salisburn A.J., O'Byrne K.J., Long L., Whitehouse R.M., Talbot D.C., et al. A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors. J. Clin. Endocrinol. Metab. 1997, 82(12):4004-4048.
145. Burt M.E., Brennan M.F. Incidence of hypercalcemia and malignant neoplasm. Arch. Surg. 1980, 115(6):704-707.
146. Vassilopoulou-Sellin R., Newman B.M., Taylor S.H., Guinee V.F. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993, 71(4):1309-1312.
147. Johnston S.R., Hammond P.J. Elevated serum parathyroid hormone-related protein and 1,25-dihydroxycholecalciferol in hypercalcemia associated with adult T-cell leukemia-lymphoma. Postgrad. Med. J. 1992, 68(803):753-755.
148. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987). Leuk. Res. 15(2-3):81-90.
149. Gellhorn A., Plimpton C.H. Hypercalcemia in malignant disease without evidence of bone destruction. Am. J. Med. 1956, 21(5):750-759.
150. Seymour J.F., Gagel R.F. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993, 82(5):1383-1394.
151. Davies M., Hayes M.E., Yin J.A., Berry J.L., Mawer E.B. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J. Clin. Endocrinol. Metab. 1994, 78(5):1202-1207.
152. Karmali R., Barker S., Hewison M., Fraher L., Katz D.R., O'Riordan J.L. Intermittent hypercalcaemia and vitamin D sensitivity in Hodgkin's disease. Postgrad. Med. J. 1990, 66(779):757-760.
153. Freeman N.J., Holik D. Uncommon syndromes and treatment manifestations of malignancy: Case 3. Richter's syndrome heralded by refractory hypercalcemia. J. Clin. Oncol. 2003, 21(1):170-172.
154. Seymour J.F., Gagel R.F., Hagemeister F.B., Dimopoulos M.A., Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin's lymphoma. Ann. Intern. Med. 1994, 121(9):633-640.
155. Walker I.R. Lymphoma with hypercalcemia. Can. Med. Assoc. J. 1974, 111(9):928-930.
156. Breslau N.A., McGuire J.L., Zerwekh J.E., Frenkel E.P., Pak C.Y. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann. Intern. Med. 1984, 100(1):1-6.
157. Mudde A.H., van den Berg H., Boshuis P.G., Breedveld F.C., Markusse H.M., Kluin P.M., et al. Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer 1987, 59(9):1543-1546.
158. Rosenthal N., Insogna K.L., Godsall J.W., Smaldone L., Waldron J.A., Stewart A.F. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1985, 60(1):29-33.
159. Rizvi A.A., Bowman M.A., Vaughters R.B., Isales C., Mulloy A.L. Primary ovarian lymphoma manifesting with severe hypercalcemia. Endocr. Pract. 2003, 9(5):389-393.
160. Adams J.S., Fernandez M., Gacad M.A., Gill P.S., Endres D.B., Rasheed S., et al. Vitamin D metabolite-mediated hypercalcemia and hypercalciuria patients with AIDS- and non-AIDS-associated lymphoma. Blood 1989, 73(1):235-239.
161. Scheinman S.J., Kelberman M.W., Tatum A.H., Zamkoff K.W. Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am. J. Med. Sci. 1991, 301(3):178-181.
162. Hibi M., Masahito H., Hara F., Tomishige H., Nishida Y., Kato T., et al. 1,25-Dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr. Hematol. Oncol. 2008, 25(1):73-78.
163. Ogose A., Kawashima H., Morita O., Hotta T., Umezu H., Endo N. Increase in serum 1,25-dihydroxyvitamin D and hypercalcemia in a patient with inflammatory myofibroblastic tumor. J. Clin. Pathol. 2003, 56(4):310-312.
164. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982, 49(10):2112-2135.
165. Cox M., Haddad J.G. Lymphoma, hypercalcemia, and the sunshine vitamin. Ann. Intern. Med. 1994, 121(9):709-712.
166. Hewison M., Kantorovich V., Liker H.R.A.J., Van Herle Cohan P, Zehnder D., et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J. Bone Miner. Res. 2003, 18(3):579-582.
167. Kremer R., Shustik C., Tabak T., Papavasiliou V., Goltzman D. Parathyroid hormone-related peptide in hematologic malignancies. Am. J. Med. 1996, 100(4):406-411.
168. Dodwell D.J., Abbas S.K., Morton A.R., Howell A. Parathyroid hormone-related protein (50-69) and response to pamidronate therapy for tumor-induced hypercalcemia. Eur. J. Cancer 1991, 27(12):1629-1633.
169. Wada S., Kitamura H., Matsuura Y., Katayama Y., Ohkawa H., Kugai N., et al. Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma. Intern. Med. 1992, 31(8):968-972.
170. 3 by human T-cell lymphotrophic virus I-transformed lymphocytes. J. Clin. Invest. 1986, 78(2):592-596.
171. Dodd R.C., Winkler C.F., Williams M.E., Bunn P.A., Gray T.K. Calcitriol levels in hypercalcemic patients with adult T-cell lymphoma. Arch. Intern. Med. 1986, 146(10):1971-1972.
172. Fukumoto S., Matsumoto T., Ikeda K., Yamashita T., Watanabe T., Yamaguchi K., et al. Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma. Arch. Intern. Med. 1988, 148(4):921-925.
173. Senba M., Kawai K. Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukemia-lymphoma. Eur. J. Haematol. 1992, 48(5):278-279.
174. Motokura T., Fukumoto S., Takahashi S., Watanabe T., Matsumoto T., Igarashi T., et al. Expression of parathyroid hormone-related protein in a human T-cell lymphotrophic virus type I-infected T-cell line. Biochem. Biophys. Res. Commun. 1988, 154(3):1182-1188.
175. Moseley J.M., Danks J.A., Grill V., Lister T.A., Horton M.A. Immunocytochemical demonstration of PTHrP protein in neoplastic tissue of HTLV-1 positive human adult T-cell leukemia/lymphoma: implications for the mechanism of hypercalcemia. Br. J. Cancer 1991, 64(4):745-748.
176. Grote T.H., Hainsworth J.D. Hypercalcemia and elevated serum calcitriol in a patient with seminoma. Arch. Intern. Med. 1987, 147(12):2212-2213.
177. Maislos M., Sobel R., Shany S. Leiomyoblastoma associated with intractable hypercalcemia and elevated 1,25-dihydroxycholecalciferol levels: treatment by hepatic enzyme induction. Arch. Intern. Med. 1985, 145(3):565-567.
178. Akai P.S., Wong T., Chang-Poon V., Green F., Whitelaw W.A., Hanley D.A. Resectable bronchogenic carcinoma presenting with hypercalcemia: tumor-associated granulomatous reaction and probable production of 1,25-dihydroxyvitamin D. Clin. Invest. Med. 1989, 12(3):212-216.
179. Stewart A.F. Hypercalcemia associated with cancer. N. Engl. J. Med. 2005, 352(4):373-379.
180. Haddad J.G., Rojanasathit S. Acute administration of 25-hydroxycholecalciferol in man. J. Clin. Endocrinol. Metab. 1976, 42(2):284-290.
181. 3) and its metabolites with different genetic variants of the serum-binding protein for these sterols. Biochem. J. 1979, 179(2):413-423.
182. 3 intakes. Arch. Biochem. Biophys. 1980, 202:43-53.
183. Jones G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 2008, 88(S). 582S-526S.
184. 3 production. Am. J. Physiol. 1990, 258(5 Pt 1):E780-E789.
185. 3 receptor up-regulation in rat osteosarcoma cells. Arch. Biochem. Biophys. 1989, 272(2):459-465.
186. 3 receptor in rats. Biochem. Biophys. Res. Commun. 1986, 137(2):742-747.
187. Reinhardt T.A., Horst R., Engstrom G., Atkins K. Ketoconazole potentiates 1,25(OH)2D-directed up-regulation of 1,25(OH)2D receptors in rat intestine and bone. Seventh Workshop on Vitamin D. Vitamin D: molecular, cellular and clinical endocrinology 1998, 233. Walter De Gruyter Inc., Berlin. A.W. Norman, K. Schaefer, H.-G. Grigoleit, D.V. Herrath (Eds.).
188. Goff J.P., Reinhardt T.A., Beckman M.J., Horst R.L. Contrasting effects of exogenous 1,25-dihydroxyvitamin D [1,25-(OH)2D] versus endogenous 1,25-(OH)2D, induced by dietary calcium restriction, on vitamin D receptors. Endocrinology 1990, 126(2):1031-1035.
189. Reinhardt T.A., Horst R. PTH down-regulates 1,25(OH)2D receptors and VDR mRNA in vitro and blocks homologous up-regulation of VDR in vitro. Endocrinology 1990, 127:942-948.
190. Haussler M.R., Cordy P.E. Metabolites and analogs of vitamin D. Which for what?. JAMA 1982, 247(6):841-844.
191. 3. Biochem. Biophys. Res. Commun. 1990, 169(3):910-915.
192. 3 blunts parathyroid hormone induction of kidney 1-hydroxylase. Arch. Biochem. Biophys. 1995, 319(2):535-539.
193. Haussler M.R. Vitamin D receptors: nature and function. Annu. Rev. Nutr. 1986, 6:527-562.
194. 3 metabolism limits receptor occupancy and target tissue responsiveness. J. Biol. Chem. 1989, 264(27):15917-15921.
195. 3 by a mechanism involving adenosine 3',5'-monophosphate in rats. Endocrinology 1986, 118(4):1583-1589.
196. Beckman M.J., Goff J.P., Reinhardt T.A., Beitz D.C., Horst R.L. In vivo regulation of rat intestinal 24-hydroxylase: potential new role of calcitonin. Endocrinology 1994, 135(5):1951-1955.
197. 3 in growing dogs. Am. J. Physiol. Endocrinol. Metab. 2003, 284(3):E505-E513.
198. St-Arnaud R., Arabian A., Travers R., Barletta F., Raval-Pandya M., Chapin K., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141(7):2658-2666.
199. Masuda S., Byford V., Arabian A., Sakai Y., Demay M.B., St-Arnaud R., et al. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005, 146(2):825-834.
200. Mallon J.P., Matuszewski D., Sheppard H. Binding specificity of the rat serum vitamin D transport protein. J. Steroid Biochem. 1980, 13(4):409-413.
201. 3 by cultured intestinal epithelial cells. J. Steroid Biochem. 1984, 20(4A):857-862.
202. Pettifor J.M., Bikle D.D., Cavaleros M., Zachen D., Kamdar M.C., Ross F.P. Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann. Intern. Med. 1995, 122(7):511-513.
203. 3 concentration. J. Clin. Invest. 1981, 67(3):589-596.
204. Bikle D.D., Siiteri P.K., Ryzen E., Haddad J.G. Serum protein-binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J. Clin. Endocrinol. Metab. 1985, 61(5):969-975.
205. Bikle D.D., Gee E., Halloran B., Haddad J.G. Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J. Clin. Invest. 1984, 74(6):1966-1971.
206. Bikle D.D., Halloran B.P., Gee E., Ryzen E., Haddad J.G. Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J. Clin. Invest. 1986, 78(3):748-752.
207. Koenig K.G., Lindberg J.S., Zerwekh J.E., Padalino P.K., Cushner H.M., Copley J.B. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int. 1992, 41(1):161-165.
208. Mendel C.M. The free hormone hypothesis: a physiologically-based mathematical model. Endocr. Rev. 1989, 10(3):232-274.
209. Edelson G.W., Kleerekoper M. Hypercalcemic crisis. Med. Clin. North Am. 1995, 79(1):79-92.
210. Ashizawa N., Arakawa S., Koide Y., Toda G., Seto S., Yano K. Hypercalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction. Intern. Med. 2003, 42(4):340-344.
211. Nussbaum S.R. Pathophysiology and management of severe hypercalcemia. Endocrinol. Metab. Clin. North Am. 1993, 22(2):343-362.
212. Scarpelli D.G., Tremblay G., Pearse A.G. A comparative cytochemical and cytologic study of vitamin D-induced nephrocalcinosis. Am. J. Pathol. 1960, 36:331-353.
213. Shetty K.R., Ajlouni K., Rosenfled P.S., Hagen T.C. Protracted vitamin D intoxication. Arch. Intern. Med. 1975, 135(7):986-988.
214. Rizzoli R., Stoermann C., Ammann P., Bonjour J.P. Hypercalcemia and hyperosteolysis in vitamin D intoxication: effects of clodronate therapy. Bone 1994, 15(2):193-198.
215. Hefti E., Trechsel U., Fleisch H., Bonjour J.P. Nature of calcemic effect of 1,25-dihydroxyvitamin D3 in experimental hypoparathyroidism. Am. J. Physiol. 1983, 244(4):E313-E316.
216. Hass G.M., Trueheart R.E., Taylor C.B., Stumpe M. An experimental histologic study of hypervitaminosis D. Am. J. Pathol. 1958, 34(3):395-431.
217. Swierczynski J., Nagel G., Zydowo M.M. Calcium content in some organs of rats treated with a toxic calciol dosis. Pharmacology 1987, 34(1):57-60.
218. Giunta J.L., Dental changes in hypervitaminosis D Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 1998, 85(4):410-413.
219. Selby P.L., Davies M., Marks J.S., Mawer E.B. Vitamin D intoxication causes hypercalcemia by increased bone resorption which responds to pamidronate. Clin. Endocrinol. (Oxf.) 1995, 43(5):531-536.
220. Adams J.S., Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann. Intern. Med. 1997, 127(3):203-206.
221. Glass A.R., Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcemic patients. J. Clin. Endocrinol. Metab. 1988, 66(5):934-938.
222. Kogan B.A., Konnak J.W., Lau K. Marked hyperoxaluria in sarcoidosis during orthophosphate therapy. J. Urol. 1982, 127(2):339-340.
223. Ettinger B., Citron J.T., Livermore B., Dolman L.I. Chlorth alidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J. Urol. 1988, 139(4):679-684.
224. Laerum E., Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta. Med. Scand. 1984, 215(4):383-389.
225. Hirst M., Feldman D. Glucocorticoids down-regulate the number of 1,25-dihydroxyvitamin D3 receptors in mouse intestine. Biochem. Biophys. Res. Commun. 1982, 105(4):1590-1596.
226. 3 and 1,25-dihydroxyvitamin D3. Endocrinology 1979, 104(2):547-551.
227. Suzuki Y., Ichikawa Y., Saito E., Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983, 32(2):151-156.
228. Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 1990, 112(5):352-364.
229. 3. Proc. Natl. Acad. Sci. USA 1974, 71(8):2996-3000.
230. Bilezikian J.P. Etiologies and therapy of hypercalcemia. Endocrinol. Metab. Clin. North Am. 1989, 18(2):389-414.
231. O'Leary T.J., Jones G., Yip A., Lohnes D., Cohanim M., Yendt E.R. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N. Engl. J. Med. 1986, 315(12):727-730.
232. Barre P.E., Gascon-Barre M., Meakins J.L., Goltzman D. Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am. J. Med. 1987, 82(6):1259-1262.
233. Adams J.S., Diz M.M., Sharma O.P. Effective reduction in the serum 1,25 dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short course chloroquine therapy. Ann. Intern. Med. 1989, 111(5):437-438.
234. Hunt B.J., Yendt E.R. The response of hypercalcemia in sarcoidosis to chloroquine. Ann. Intern. Med. 1963, 59(4):554-564.
235. Adams J.S., Kantorovich V. Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. J. Clin. Endocrinol. Metab. 1999, 84(2):799-801.
236. Adams J.S., Sharma O.P., Diz M.M., Endres D.B. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J. Clin. Endocrinol. Metab. 1990, 70(4):1090-1095.
237. Young C., Burrows R., Katz J., Beynon H. Hypercalcaemia in sarcoidosis. Lancet 1999, 353(9150):374.
238. Conron M., Young C., Beynon H.L. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 2000, 39(7):707-713.
239. Shane E., Irani D. Hypercalcemia: pathogenesis, clinical manifestations, differential diagnosis, and management. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2006, 179. American Society for Bone and Mineral Research, Washington. Sixth ed. M.J. Favus (Ed.).